✅ Model Answer:
• Diagnosis: Aminoglycoside-induced ototoxicity (sensorineural hearing loss) — high-frequency SNHL (4-8 kHz) is classic. Gentamicin exposure (multiple courses) is the cause. Normal renal function excludes significant renal impairment.
• Any other test: ABR shows Elevated thresholds, consistent with SNHLGenetic testing for m.1555A>G mitochondrial mutation (predisposes to aminoglycoside ototoxicity), vestibular function testing (balance issues), tinnitus assessment, renal function (already normal).
• What to do next: Avoid future aminoglycosides if possible (use alternative antibiotics). Hearing aids (if functional). Tinnitus management. Refer to audiology for rehabilitation. Consider FM system for school.
• Follow-up plan: Serial audiometry (monitor for progression). Consider hearing aids, FM system for school. Genetic counseling if mutation found. Vestibular rehabilitation if balance issues. Monitor for future hearing changes.

✅ Model Answer:
• Aminoglycosides: Gentamicin, tobramycin, amikacin, streptomycin
- Mechanism: Accumulate in the inner ear → damage outer hair cells (base to apex) → high-frequency SNHL (first sign)
- Risk: Higher with multiple courses, high doses, renal impairment, genetic predisposition (m.1555A>G)
• Loop diuretics: Furosemide, ethacrynic acid
- Mechanism: Inhibit the Na-K-2Cl cotransporter in the stria vascularis → temporary hearing loss (usually reversible)
• Chemotherapy: Cisplatin, carboplatin
- Mechanism: Damage outer hair cells → high-frequency SNHL, often permanent
• Salicylates: Aspirin (high doses)
- Mechanism: Reversible SNHL, usually temporary
• Macrolides: Erythromycin, azithromycin (less common)

✅ Model Answer:
• m.1555A>G mutation: Mitochondrial DNA mutation (A to G transition at position 1555 in the 12S rRNA gene).
• Inheritance: Maternal inheritance (mitochondrial DNA).
• Prevalence: 1 in 500 to 1 in 1,000 people (higher in some populations).
• Mechanism: Mutation makes the mitochondrial ribosome more susceptible to aminoglycosides → increased uptake → hair cell damage.
• Clinical significance: Patients with this mutation can develop hearing loss even after single dose of aminoglycosides (previously normal hearing).
• Testing: Genetic testing should be considered before aminoglycoside use in high-risk patients (or if there is a family history).
• Implication: If positive, aminoglycosides should be avoided for life.

✅ Model Answer:
• Classic pattern: High-frequency SNHL (4,000-8,000 Hz) — early loss at 6,000-8,000 Hz, progresses to lower frequencies if continued exposure.
• Why high frequencies? Aminoglycosides cause base-to-apex hair cell damage (basal turn of the cochlea processes high frequencies).
• Progression: Initially asymptomatic (patient may not notice hearing loss).
- With continued exposure: Frequency range expands → speech frequencies affected (500-2000 Hz) → noticeable hearing loss.
• OAE: Absent at high frequencies (correlates with hair cell damage).
• ABR: Elevated thresholds, consistent with SNHL.
• Vestibular: May also cause vestibular damage (dizziness, ataxia) — especially with gentamicin.

✅ Model Answer:
• Prevention is key:
- Avoid aminoglycosides if possible, especially in patients with m.1555A>G mutation, renal impairment, or cystic fibrosis (repeated courses).
- Monitor drug levels: Peak and trough levels (ensure therapeutic but not toxic).
- Baseline and serial audiometry: Before and during treatment.
• Treatment:
- Hearing aids: If speech frequencies are affected (typically >30 dB loss).
- FM systems: For classroom/school use (improves signal-to-noise ratio).
- Tinnitus management: Counseling, sound therapy (if tinnitus present).
- Vestibular rehabilitation: If dizziness or imbalance.
- Cochlear implant: If severe-profound SNHL (but rare for ototoxicity).
- Genetic counseling: If m.1555A>G mutation found.

✅ Model Answer:
• Pre-treatment:
- Baseline audiometry: Before starting aminoglycosides (especially in patients with CF, or multiple courses).
- Renal function: Assess baseline renal function (aminoglycosides are renally excreted).
- Genetic testing: Consider m.1555A>G testing if family history or high-risk populations.
• During treatment:
- Peak and trough levels: Monitor serum levels (therapeutic range: peak 5-10 µg/mL, trough <2 µg/mL).
- Serial audiometry: If possible (every 2-3 days for high-frequency testing).
- Early signs: High-frequency hearing loss or tinnitus → discontinue or switch to alternative.
• Post-treatment:
- Follow-up audiometry: 1-3 months after treatment (late-onset hearing loss possible).
- Monitor for progression: Even after discontinuation, hearing loss can progress.

✅ Model Answer:
• Complications:
- Speech/language delay: If hearing loss affects speech frequencies (>30 dB), especially in younger children
- Academic difficulties: Classroom performance, reading, attention issues
- Tinnitus: Ringing in the ears (can be debilitating, affect concentration, sleep)
- Vestibular dysfunction: Dizziness, imbalance, ataxia (gentamicin is particularly vestibulotoxic)
- Social/emotional: Social isolation, depression, anxiety (especially in adolescents)
- Educational: Need for school accommodations (FM systems, preferential seating)
- Career implications: Certain careers (music, aviation, military) may be impacted
- Progression: Hearing loss may worsen even after drug discontinuation (delayed ototoxicity)

✅ Model Answer:
• Prognosis:
- Irreversible: Aminoglycoside-induced hearing loss is usually permanent and may be progressive (can continue to worsen even after stopping the drug).
- High-frequency: Initially affects high frequencies (may not be noticed).
- Speech frequencies: If affected, hearing aids can help.
- Cochlear implant: Rarely needed unless severe-profound (more common with chemotherapy).
• Long-term outcomes:
- Early detection: Allows early intervention and support.
- Hearing aids: Provide good outcomes for high-frequency loss with speech frequency involvement.
- School support: FM systems, preferential seating, IEP/504 plans.
- Genetic counseling: If m.1555A>G mutation found (maternal family members at risk).
- Quality of life: Good with appropriate support; may need psychosocial support for adolescents.
- Future: Aminoglycosides should be avoided for life (especially if m.1555A>G mutation).